Carisma Therapeutics, Inc.
Carisma Therapeutics, Inc. (CARM) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
carm · stock forecast · 6 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 6 Wall Street analysts in the past 3 months
Hold
6 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$6.00
Consensus
$6.00
+31562.3% upside
Low
$6.00
Median: $6 · Last Close: $0.02
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $0.02 | ↑ 0.00% |
1-day model range: $0.02–$0.02. Peak: $0.02 (+0.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CARM · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-08-08 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-04-01 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-01-17 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-01-13 | D. Boral Capital | Maintains | Buy→Buy |
| 2024-12-16 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2024-12-12 | Baird | Downgrade ↓ | Outperform→Neutral |
| 2024-12-12 | D. Boral Capital | Maintains | Buy→Buy |
| 2024-12-11 | Evercore ISI Group | Downgrade ↓ | Outperform→In Line |
| 2024-12-10 | BTIG | Downgrade ↓ | Buy→Neutral |
| 2024-12-09 | D. Boral Capital | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Carisma Therapeutics, Inc. (CARM) stock. Of the recent 24 rating actions, 0 were upgrades and 4 were downgrades. 6 analysts currently cover CARM.
Analyst Recommendation Trends
CARM analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$15M
↓ 65.3% YoY
Revenue Next Year
$9M
↓ 39.2% YoY
EPS This Year
$-0.69
EPS Next Year
$-0.52
↓ 24.7% YoY
EPS ForecastReported vs Estimated
Analysts forecast CARM EPS of $-0.69 for the current fiscal year, based on estimates from 1 analysts. The CARM revenue forecast is $15M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CARM stock forecast is supported by two independent data sources: analyst consensus ratings from 6 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CARM price target is $6.00 (+31562.3% upside), with an analyst consensus of Hold.
The CARM short-term stock prediction for tomorrow is $0.02 (+0.00%).
Carisma Therapeutics, Inc. trades on OTC under the ticker CARM. The CARM stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 33% of covering analysts.
Frequently asked questions
CARM forecast · 8 questionsAccording to 6 Wall Street analysts, the average 12-month CARM price target is $6.00, with a high forecast of $6.00 and a low of $6.00. The median price target is shown in the chart above when available. This implies +31562.3% potential upside from the current price of $0.02.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.